---
title: Artificial Intelligence–Powered and Manual Assessment of PD-L1 Are Comparable in Predicting Response to Neoadjuvant Atezolizumab in Patients With Resectable Non-Squamous, Non-Small Cell Lung Cancer
description: Artificial Intelligence–Powered and Manual Assessment of PD-L1 Are Comparable in Predicting Response to Neoadjuvant Atezolizumab in Patients With Resectable Non-Squamous, Non-Small Cell Lung Cancer
---

[PathAI Resources ](https://www.pathai.com/resources)

# [Artificial Intelligence–Powered and Manual Assessment of PD-L1 Are Comparable in Predicting Response to Neoadjuvant Atezolizumab in Patients With Resectable Non-Squamous, Non-Small Cell Lung Cancer](https://www.pathai.com/resources/artificial-intelligence-powered-and-manual-assessment-of-pd-l1-are-comparable-in-predicting-response-to-neoadjuvant-atezolizumab-in-patients-with-resectable-n)

 Written by [Admin](https://www.pathai.com/resources/author/admin) | Apr 8, 2022 4:00:00 AM

## Study Background

 • Immunohistochemistry (IHC) evaluation of programmed death-ligand 1 (PD-L1) expression is a reliable predictor of the efficacy of anti–PD-L1/programmed cell death protein 1 (PD-1) cancer immunotherapy in patients with resected and metastatic non-small cell lung cancer (NSCLC)

• Exploratory analyses in patients with metastatic NSCLC suggest a potentially limited enrichment for the efficacy of anti–PD-L1/PD-1 therapy in patients with high PD-L1 expression and squamous histology.2 Data in early NSCLC are limited to date

• Preoperative treatment with atezolizumab (anti–PD-L1 antibody) in patients with untreated early-stage resectable NSCLC resulted in a 20% major pathologic response (MPR) rate in the LCMC3 Phase II study

• Computer vision can be used on pathology slides to identify biological entities, including cell types, tissue types, and biomarker expression, and to compute slide-level scores or digitally quantify pathology features

• Using manual and digital PD-L1 scoring methods, we assessed PD-L1 expression in tumor cells as a potential predictor of pathologic response to neoadjuvant atezolizumab treatment in patients with non-squamous and squamous NSCLC tumors Abel et al.

[View Poster](https://www.pathai.com/hubfs/2025%20Assets/FINAL_SUBMITTED_AACR_LCMC3_PathAI_DigitalResponse_Poster_DRAFT05_2022MAR18.pdf)

[View full post](https://www.pathai.com/resources/artificial-intelligence-powered-and-manual-assessment-of-pd-l1-are-comparable-in-predicting-response-to-neoadjuvant-atezolizumab-in-patients-with-resectable-n)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Admin"
  },
  "dateModified" : "2025-08-06T19:55:21.710Z",
  "datePublished" : "2022-04-08T04:00:00Z",
  "headline" : "Artificial Intelligence–Powered and Manual Assessment of PD-L1 Are Comparable in Predicting Response to Neoadjuvant Atezolizumab in Patients With Resectable Non-Squamous, Non-Small Cell Lung Cancer",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://www.pathai.com/resources/artificial-intelligence-powered-and-manual-assessment-of-pd-l1-are-comparable-in-predicting-response-to-neoadjuvant-atezolizumab-in-patients-with-resectable-n",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "PathAI Resources"
  }
}
```